Article

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer

2020-08-28

Abstract excerpt

<h4>ABSTRACT</h4> Resistance to targeted therapies is an important clinical problem in HER2-positive (HER2+) breast cancer. “Drug-tolerant persisters” (DTPs), a sub-population of cancer cells that survive via reversible, non-genetic mechanisms, are implicated in resistance to tyrosine kinase inhibitors (TKIs) in other malignancies, but DTPs following HER2 TKI exposure have not been well characterized. We found th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1d3a0578-7e6f-5e1c-a843-6ee1f4625d7e
DOI: 10.1101/2020.08.28.273029

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast CancerDOI 10.1101/2020.08.28.273029Read

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read

Chemotherapy reshapes cellular clonal landscape via persister programs in breast cancer xenograftsSemantic proximity Read

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programsSemantic proximity Read

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for TherapySemantic proximity Read

Cancer drug-tolerant persister cells: from biological questions to clinical opportunitiesSemantic proximity Read

Long-term multi-modal recording reveals unpredictable nongenetic adaptation routes in dormant breast cancer cells.Semantic proximity Read

Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axisSemantic proximity Read

Drug-Tolerant Persister Cells in Cancer Therapy ResistanceSemantic proximity Read

Metabolic orchestration of drug-tolerant persister cells in cancerSemantic proximity Read

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitorsSemantic proximity Read

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Semantic proximity Read

Dormancy, stemness, and therapy resistance: interconnected players in cancer evolutionSemantic proximity Read